The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® ( RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

In the Lehigh Valley, cases of the flu and RSV are particularly prevalent compared with many other parts of the state.

Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

Flu season is here in New Jersey, but other illnesses are in full swing in the Garden State. Here are the symptoms and how ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

When broken down by state, most of the country is experiencing elevated respiratory illness, including a few states with ...

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.